Defective NK cells in acute myeloid leukemia patients at diagnosis are associated with blast transcriptional signatures of immune evasion

Journal of Immunology

Volumn 195, Issue 6, 2015, Pages 2580-2590

  Khaznadar, Zena ^a,b   Boissel, Nicolas ^b,c,d   Agaugué, Sophie ^a,b   Henry, Guylaine ^c   Cheok, Meyling ^a,e   Vignon, Marguerite ^a,b   Geromin, Daniela ^b,c   Cayuela, Jean Michel ^b,c   Castaigne, Sylvie ^f   Pautas, Cécile ^g,h   Raffoux, Emmanuel ^c,d   Lachuer, Joel ^i,j,k   Sigaux, François ^b   Preudhomme, Claude ^a,e   Dombret, Hervé ^b,c,d   Dulphy, Nicolas ^a,b,c   Toubert, Antoine ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^g UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^j UNIVERSITÉ DE LYON   (France)

^k ProfileXpert   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; DNAX ACCESSORY MOLECULE 1; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR 1; HLA DR ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 15; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; CXCR4 PROTEIN, HUMAN; GAMMA INTERFERON RECEPTOR; IFNGR2 PROTEIN, HUMAN; IL15 PROTEIN, HUMAN; INTERFERON RECEPTOR; LEUKOCYTE ANTIGEN; SIALYLTRANSFERASE; ST6GAL1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CD74 GENE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CXCR4 GENE; CYTOGENETICS; DOWN REGULATION; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HLA DRA GENE; HLA DRB1 GENE; HUMAN; ICAM1 GENE; IFNGR1 GENE; IFNGR2 GENE; IL15 GENE; IMMUNE EVASION; LYMPHOCYTE FUNCTION; MALE; NATURAL KILLER CELL; ONCOGENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PVR GENE; SIGNAL TRANSDUCTION; SURVIVAL TIME; VALIDATION PROCESS; AGED; BIOSYNTHESIS; CYTOTOXICITY; GENETICS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MIDDLE AGED; TUMOR ESCAPE; YOUNG ADULT;

ADULT; AGED; ANTIGENS, CD; CELL ADHESION MOLECULES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HLA-DR ALPHA-CHAINS; HLA-DRB1 CHAINS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-15; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RECEPTORS, CXCR4; RECEPTORS, INTERFERON; RECEPTORS, NATURAL KILLER CELL; SIALYLTRANSFERASES; TUMOR ESCAPE; YOUNG ADULT;

EID: 84941788007     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500262     Document Type: Article

References (58)

1. Estey, E., and H. Döhner. 2006. Acute myeloid leukaemia. Lancet 368: 1894-1907.
2. Miller, J. S., Y. Soignier, A. Panoskaltsis-Mortari, S. A. McNearney, G. H. Yun, S. K. Fautsch, D. McKenna, C. Le, T. E. Defor, L. J. Burns, et al. 2005. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105: 3051-3057.
3. Curti, A., L. Ruggeri, A. D'Addio, A. Bontadini, E. Dan, M. R. Motta, S. Trabanelli, V. Giudice, E. Urbani, G. Martinelli, et al. 2011. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 118: 3273-3279.
4. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, et al. 2002. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295: 2097-2100.
5. Costello, R. T., C. Fauriat, S. Sivori, E. Marcenaro, and D. Olive. 2004. NK cells: innate immunity against hematological malignancies? Trends Immunol. 25: 328-333.
6. Bryceson, Y. T., and E. O. Long. 2008. Line of attack: NK cell specificity and integration of signals. Curr. Opin. Immunol. 20: 344-352.
7. Yu, J., A. G. Freud, and M. A. Caligiuri. 2013. Location and cellular stages of natural killer cell development. Trends Immunol. 34: 573-582.
8. Verheyden, S., and C. Demanet. 2008. NK cell receptors and their ligands in leukemia. Leukemia 22: 249-257.
9. Pende, D., G. M. Spaggiari, S. Marcenaro, S. Martini, P. Rivera, A. Capobianco, M. Falco, E. Lanino, I. Pierri, R. Zambello, et al. 2005. Analysis of the receptorligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood 105: 2066-2073.
10. Fauriat, C., S. Just-Landi, F. Mallet, C. Arnoulet, D. Sainty, D. Olive, and R. T. Costello. 2007. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction. Blood 109: 323-330.
11. Bottino, C., R. Castriconi, D. Pende, P. Rivera, M. Nanni, B. Carnemolla, C. Cantoni, J. Grassi, S. Marcenaro, N. Reymond, et al. 2003. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J. Exp. Med. 198: 557-567.
12. Pende, D., C. Bottino, R. Castriconi, C. Cantoni, S. Marcenaro, P. Rivera, G. M. Spaggiari, A. Dondero, B. Carnemolla, N. Reymond, et al. 2005. PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol. Immunol. 42: 463-469.
13. Poggi, A., S. Catellani, A. Garuti, I. Pierri, M. Gobbi, and M. R. Zocchi. 2009. Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. Leukemia 23: 641-648.
14. Rohner, A., U. Langenkamp, U. Siegler, C. P. Kalberer, and A. Wodnar-Filipowicz. 2007. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis. Leuk. Res. 31: 1393-1402.
15. Stringaris, K., T. Sekine, A. Khoder, A. Alsuliman, B. Razzaghi, R. Sargeant, J. Pavlu, G. Brisley, H. de Lavallade, A. Sarvaria, et al. 2014. Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 99: 836-847.
16. Bullinger, L., K. Döhner, E. Bair, S. Fröhling, R. F. Schlenk, R. Tibshirani, H. Döhner, and J. R. Pollack. 2004. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350: 1605-1616.
17. Metzeler, K. H., M. Hummel, C. D. Bloomfield, K. Spiekermann, J. Braess, M. C. Sauerland, A. Heinecke, M. Radmacher, G. Marcucci, S. P. Whitman, et al. 2008. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112: 4193-4201.
18. Valk, P. J., R. G. Verhaak, M. A. Beijen, C. A. Erpelinck, S. Barjesteh van Waalwijk van Doorn-Khosrovani, J. M. Boer, H. B. Beverloo, M. J. Moorhouse, P. J. van der Spek, B. Löwenberg, and R. Delwel. 2004. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350: 1617-1628.
19. Rapin, N., F. O. Bagger, J. Jendholm, H. Mora-Jensen, A. Krogh, A. Kohlmann, C. Thiede, N. Borregaard, L. Bullinger, O. Winther, et al. 2014. Comparing cancer vs normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood 123: 894-904.
20. Bennett, J. M., D. Catovsky, M. T. Daniel, G. Flandrin, D. A. Galton, H. R. Gralnick, and C. Sultan. 1976. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol. 33: 451-458.
21. Grimwade, D., H. Walker, F. Oliver, K. Wheatley, C. Harrison, G. Harrison, J. Rees, I. Hann, R. Stevens, A. Burnett, et al. 1998. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92: 2322-2333.
22. Mitelman, F., ed. 1995. ISCN 1995. An International System for Human Cytogenetic Nomenclature. Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S Karger AG, Memphis, TN.
23. Castaigne, S., C. Pautas, C. Terré, E. Raffoux, D. Bordessoule, J. N. Bastie, O. Legrand, X. Thomas, P. Turlure, O. Reman, et al. 2012. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379: 1508-1516.
24. Dulphy, N., P. Haas, M. Busson, S. Belhadj, R. Peffault de Latour, M. Robin, M. Carmagnat, P. Loiseau, R. Tamouza, C. Scieux, et al. 2008. An unusual CD56bright CD16low NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. J. Immunol. 181: 2227-2237.
25. Sturn, A., J. Quackenbush, and Z. Trajanoski. 2002. Genesis: cluster analysis of microarray data. Bioinformatics 18: 207-208.
26. Edgar, R., M. Domrachev, and A. E. Lash. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30: 207-210.
27. Huang, W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4: 44-57.
28. Storey, J. D. 2002. A direct approach to false discovery rates. J. R. Stat. Soc., B 64: 479-498.
29. Gentleman, R. C., V. J. Carey, D. M. Bates, B. Bolstad, M. Dettling, S. Dudoit, B. Ellis, L. Gautier, Y. Ge, J. Gentry, et al. 2004. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5: R80.
30. Subramanian, A., P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, and J. P. Mesirov. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102: 15545-15550.
31. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22: 633-640.
32. Reikvam, H., A. M. yan, K. H. Kalland, R. Hovland, K. J. Hatfield, and . Bruserud. 2013. Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Prolif. 46: 554-562.
33. Jaatinen, T., H. Hemmoranta, S. Hautaniemi, J. Niemi, D. Nicorici, J. Laine, O. Yli-Harja, and J. Partanen. 2006. Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells 24: 631-641.
34. Gal, H., N. Amariglio, L. Trakhtenbrot, J. Jacob-Hirsh, O. Margalit, A. Avigdor, A. Nagler, S. Tavor, L. Ein-Dor, T. Lapidot, et al. 2006. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 20: 2147-2154.
35. Eppert, K., K. Takenaka, E. R. Lechman, L. Waldron, B. Nilsson, P. van Galen, K. H. Metzeler, A. Poeppl, V. Ling, J. Beyene, et al. 2011. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 17: 1086-1093.
36. Löwenberg, B., W. L. van Putten, I. P. Touw, R. Delwel, and V. Santini. 1993. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N. Engl. J. Med. 328: 614-619.
37. Hunter, A. E., S. Y. Rogers, I. A. Roberts, A. J. Barrett, and N. Russell. 1993. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 82: 899-903.
38. Armstrong, S. A., J. E. Staunton, L. B. Silverman, R. Pieters, M. L. den Boer, M. D. Minden, S. E. Sallan, E. S. Lander, T. R. Golub, and S. J. Korsmeyer. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30: 41-47.
39. Faber, J., A. V. Krivtsov, M. C. Stubbs, R. Wright, T. N. Davis, M. van den Heuvel-Eibrink, C. M. Zwaan, A. L. Kung, and S. A. Armstrong. 2009. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 113: 2375-2385.
40. Mullighan, C. G., A. Kennedy, X. Zhou, I. Radtke, L. A. Phillips, S. A. Shurtleff, and J. R. Downing. 2007. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 21: 2000-2009.
41. Verhaak, R. G., C. S. Goudswaard, W. van Putten, M. A. Bijl, M. A. Sanders, W. Hugens, A. G. Uitterlinden, C. A. Erpelinck, R. Delwel, B. Löwenberg, and P. J. Valk. 2005. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106: 3747-3754.
42. Barbie, D. A., P. Tamayo, J. S. Boehm, S. Y. Kim, S. E. Moody, I. F. Dunn, A. C. Schinzel, P. Sandy, E. Meylan, C. Scholl, et al. 2009. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112.
43. Ebert, B. L., J. Pretz, J. Bosco, C. Y. Chang, P. Tamayo, N. Galili, A. Raza, D. E. Root, E. Attar, S. R. Ellis, and T. R. Golub. 2008. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 451: 335-339.
44. Hurtz, C., K. Hatzi, L. Cerchietti, M. Braig, E. Park, Y. M. Kim, S. Herzog, P. Ramezani-Rad, H. Jumaa, M. C. Müller, et al. 2011. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J. Exp. Med. 208: 2163-2174.
45. Phan, R. T., and R. Dalla-Favera. 2004. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature 432: 635-639.
46. Ranuncolo, S. M., J. M. Polo, and A. Melnick. 2008. BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood Cells Mol. Dis. 41: 95-99.
47. Costello, R. T., S. Sivori, E. Marcenaro, M. Lafage-Pochitaloff, M. J. Mozziconacci, D. Reviron, J. A. Gastaut, D. Pende, D. Olive, and A. Moretta. 2002. Defective expression and function of natural killer celltriggering receptors in patients with acute myeloid leukemia. Blood 99: 3661-3667.
48. Sanchez-Correa, B., I. Gayoso, J. M. Bergua, J. G. Casado, S. Morgado, R. Solana, and R. Tarazona. 2012. Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol. Cell Biol. 90: 109-115.
49. Khaznadar, Z., G. Henry, N. Setterblad, S. Agaugue, E. Raffoux, N. Boissel, H. Dombret, A. Toubert, and N. Dulphy. 2014. Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. Eur. J. Immunol. 44: 3068-3080.
50. Patel, J. P., M. Gönen, M. E. Figueroa, H. Fernandez, Z. Sun, J. Racevskis, P. Van Vlierberghe, I. Dolgalev, S. Thomas, O. Aminova, et al. 2012. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N. Engl. J. Med. 366: 1079-1089.
51. Cancer Genome Atlas Research Network. 2013. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368: 2059-2074.
52. Tiacci, E., V. Grossmann, M. P. Martelli, A. Kohlmann, T. Haferlach, and B. Falini. 2012. The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Haematologica 97: 3-5.
53. Damm, F., V. Chesnais, Y. Nagata, K. Yoshida, L. Scourzic, Y. Okuno, R. Itzykson, M. Sanada, Y. Shiraishi, V. Gelsi-Boyer, et al. 2013. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood 122: 3169-3177.
54. Solana, R., C. Campos, A. Pera, and R. Tarazona. 2014. Shaping of NK cell subsets by aging. Curr. Opin. Immunol. 29: 56-61.
55. Szczepanski, M. J., M. Szajnik, A. Welsh, K. A. Foon, T. L. Whiteside, and M. Boyiadzis. 2010. Interleukin-15 enhances natural killer cell cytotoxicity in patients with acute myeloid leukemia by upregulating the activating NK cell receptors. Cancer Immunol. Immunother. 59: 73-79.
56. Seymour, L., A. Tinker, H. Hirte, N. Wagtmann, and P. Dodion. 2015. O3.2Phase I and dose ranging, phase II studies with IPH2201, a humanized monoclonal antibody targeting HLA-E receptor CD94/NKG2A. Ann. Oncol. 26(Suppl. 2): ii3.
57. Vey, N., J. H. Bourhis, N. Boissel, D. Bordessoule, T. Prebet, A. Charbonnier, A. Etienne, P. Andre, F. Romagne, D. Benson, et al. 2012. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120: 4317-4323.
58. Diermayr, S., H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al. 2008. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities. Blood 111: 1428-1436.